The SEER database did not provide sufficient information on systemic therapy, such as CT regimens in patients with IBC, Her2-positive patients treated with or without trastuzumab, and hormone receptor-positive patients treated with or without hormonal therapy. This evidence concerns the gene NR4A1 and inflammatory breast carcinoma.